Breakthrough in immunotherapy: Novartis receives first ever FDA approval for a CAR-T cell therapy fo
Novartis announced today that the US Food and Drug Administration (FDA) has approved Kymriah(TM) (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Kymriah is a novel immunocellular therapy and a one-time treatment that uses a patient's own T cells to fight cancer. Kymriah is the first therapy based on gene transfer approved by the FDA.
For details, please check this out:
